share_log

6-K: 15.7% Sales Growth Boosted by Earlier-Than-Anticipated Vaccine Sales; 2024 Business Eps Guidance Raised Due to Strong Business Performance

6-K: 15.7% Sales Growth Boosted by Earlier-Than-Anticipated Vaccine Sales; 2024 Business Eps Guidance Raised Due to Strong Business Performance

6-K:疫苗销售早于预期,销售额增长15.7%;业务表现强劲,2024年业务每股收益指导上调
美股SEC公告 ·  10/25 12:42
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息